Thanks. I don't expect much variation based on the data shown in Int J Inf Dis paper Figure 2 (D and E), N=10. Is there some other data you are aware of?

Can you shed any light on how accurate is the RO testing, in terms of test-retest reliability on the same sample? or do you know what is the truth about HIV BLA and RO testing by InCellDx: did FDA reject the InCellDx methods (which seems to be what Nader indicated on one of the calls and in an interview), and if so, why? A recent announcement from InCellDX seemed to indicate they were marketing the test, so does that mean FDA now approves of the InCellDx assay as described in the paper?